Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

Please provide your email address to receive an email when new articles are posted on . It is an exciting time in the treatment of renal anemia, with several new therapies recently launched or ...

Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

Please provide your email address to receive an email when new articles are posted on . Among surveyed nephrologists, familiarity with Roche’s Mircera is low, but is still second highest among six ...

Roche Pharmaceuticals quickly rejected claims that Roche planted secret molecule in Mircera which allowed for detection of the CERA class drug at the 2008 Tour de France. John Fahey, WADA president, ...

ZURICH, May 25 (Reuters) - Roche Holding AG's potential blockbuster drug Mircera has been cleared by European authorities, who recommended allowing sales to treat anaemia linked to kidney disease.